Drug Type Mesenchymal stem cell therapy |
Synonyms ABCB5+-cells, allo-APZ2-ACLF, allo-APZ2-CVU + [9] |
Target- |
Mechanism Cell replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Epidermolysis Bullosa | Phase 3 | AT | 01 Feb 2023 | |
Epidermolysis Bullosa Dystrophica | Phase 3 | US | 30 Jan 2022 | |
Chronic venous insufficiency | Phase 2 | US | 30 Jan 2022 | |
Diabetic foot ulcer | Phase 2 | US | 30 Jan 2022 | |
Varicose Ulcer | Phase 2 | DE | 18 Aug 2021 | |
Wounds and Injuries | Phase 2 | DE | 18 Aug 2021 | |
Acute-On-Chronic Liver Failure | Phase 2 | DE | 22 Mar 2019 | |
Peripheral arterial occlusive disease | Phase 2 | AT | 05 Mar 2018 | |
Peripheral arterial occlusive disease | Phase 2 | CZ | 05 Mar 2018 | |
Peripheral arterial occlusive disease | Phase 2 | DE | 05 Mar 2018 |
Phase 1/2 | 16 | ABCB5+ mesenchymal stem cells | ukgawaduee(hqjrjlyslx) = mfmovmtstu czmnwdsfwf (ynzxjqfhys ) View more | Positive | 22 Nov 2021 |